mAb 2C7 + TDF IVR

Phase:Open Label
Principal Investigator(s):RAM, SANJAY
Objective:This collaborative proposal between UMass, Planet Biotechnology, Inc., Oak Crest Institute of Science and MassBiologics seeks to develop intravaginal rings (IVRs) to deliver fully humanized mAb 2C7 in combination with tenofovir disoproxil fumarate (intravaginal TDF; proven efficacious in preventing HIV transmission to women) to prevent gonorrhea and HIV infections.
Prevention Option(s):Microbicides
Study Design:
Arms and Assigned Interventions
Mode of Delivery
Official Code: mAb 2C7 + TDF IVR
Start Date
End Date
April 1, 2018
March 1, 2023
Age range: ↔ any
Population:Cisgender Men